When further comparing the clinically relevant markers LAG-3 and PD-1, the intratumoral immune cells in the CD3high subgroup showed a higher expression of CD4+ LAG-3 (p = .01, median 2.8% vs .2%), CD8+ LAG-3 (p = .02 median 6.4% vs .9%), CD4+ PD-1 (p = .02, median 50.6% vs 18.1%) and CD8+ PD-1 (p = .008, median 71.4% vs 25.5%), whereas no difference was found in the NKhigh group between the tumor and the healthy tissue (Figure 3e,f and Supplementary Fig. S5B, respectively). The gene discussed is CD8A; the disease is neoplasm.